Inactive Instrument

All News Opko Health Inc. Nyse

Equities

US68375N1037

End-of-day quote Nyse Other stock markets
- ^USD	-

Mar. 28	Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	MT
Mar. 20	Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

InvestorBrandMedia: Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. (NYSEAMERICAN: ATNM) Amidst Groundbreaking Cancer Therapy Innovations	Apr. 01	AQ
Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	Mar. 28	MT
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	Mar. 20	AQ
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	Mar. 20	CI
OPKO Health : Immediate Report	Mar. 15	PU
Opko Health Insider Bought Shares Worth $444,300, According to a Recent SEC Filing	Mar. 14	MT
Opko Health Insider Bought Shares Worth $463,750, According to a Recent SEC Filing	Mar. 13	MT
Opko Health Insider Bought Shares Worth $559,380, According to a Recent SEC Filing	Mar. 12	MT
OPKO Health - AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV	Mar. 06	AQ
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV	Mar. 05	AQ
OPKO Health : Immediate Report	Mar. 02	PU
OPKO Health : Report of Periodic or Interim Report	Mar. 02	PU
Barrington Cuts Price Target on OPKO Health to $1.50 From $2, Maintains Outperform Rating	Feb. 28	MT
OPKO Health: Q4 Earnings Snapshot	Feb. 27	AQ
Transcript : OPKO Health, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Earnings Flash (OPK) OPKO HEALTH Reports Q4 Revenue $181.9M, vs. Street Est of $177.5M	Feb. 27	MT
OPKO Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results	Feb. 27	AQ
Drugmakers deepen efforts to tap into booming market for obesity drugs	Feb. 27	RE
Thinking about buying stock in Intuitive Machines, OPKO Health, Ardelyx, AXT Inc, or Clearmind Medicine?	Feb. 23	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Opko Health Inc. Nyse

Equities

US68375N1037

All News

Filters